# FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat

Source: https://onco.cc/trials/nct05727163/  
OnCo record `nct05727163` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of dexamethasone, fOLFOX (5-FU, leucovorin, oxaliplatin), fluorouracil (5-FU), fOLFIRI (5-FU, leucovorin, irinotecan) and other drugs in colorectal cancer, run by Sun Yat-sen University, now recruiting.

## Summary

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients is a phase 2, randomised interventional study registered as NCT05727163 by Sun Yat-sen University, with a registry enrolment figure of 194 participants, started 2022-07-29 and due to reach its primary completion in 2026-12-31. Interventions recorded: Dexamethasone; Anisodamine; Oxaliplatin; Leucovorin; Fluorouracil; Irinotecan; Bevacizumab; Oxaliplatin; Leucovorin; Fluorouracil. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective Remission Rate (ORR). Colorectal eligibility wording from the registry: "Histologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05727163
- Phase: 2
- Setting: FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical Study
- Sponsor: Sun Yat-sen University
- Enrolled: 194

## Sources

- ClinicalTrials.gov NCT05727163: https://clinicaltrials.gov/study/NCT05727163

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05727163.json